Skip to main content
CDNA
NASDAQ Industrial Applications And Services

CareDx Reports Strong Preliminary Q4 & FY25 Results, Announces $88M Full-Year Share Repurchase

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Diagnostics & Research Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$17.68
Mkt Cap
$885.67M
52W Low
$10.96
52W High
$25.95
52W Position info
61% above low
Off High info
32% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

CDNA sits 61% above its 52-week low of $10.96.

Summary

CareDx announced robust preliminary financial results for Q4 and full-year 2025, highlighted by significant revenue growth across all segments and a substantial $88 million share repurchase program for the year.


Key Events · Earnings and Guidance · CDNA

  • Strong Revenue Growth

    Preliminary Q4 2025 revenue increased 25% year-over-year to $108 million, with full-year revenue reaching $380 million, up 14% year-over-year.

  • Significant Share Repurchase

    The company repurchased $88 million worth of shares during 2025, including $12 million in Q4, demonstrating a strong commitment to returning capital to shareholders.

  • Healthy Cash Position

    CareDx reported approximately $200 million in cash, cash equivalents, and marketable securities as of December 31, 2025.

  • Operational Momentum

    Testing services volume increased 17% in Q4 and 14% for the full year, with patient & digital solutions revenue growing 47% in Q4.


Analysis · CDNA · Industrial Applications And Services

The preliminary financial results indicate strong operational performance for CareDx, with double-digit revenue growth in both the fourth quarter and the full year 2025. The substantial $88 million share repurchase program, representing a significant portion of the company's market capitalization, signals strong management confidence in the company's valuation and financial health. This capital allocation strategy, combined with a healthy cash position, suggests a positive outlook for the company's future performance and shareholder returns.

How filings like this one have moved

In the 30 days to Sep 18, 2026, 35.4% of the 1144 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.40%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CDNA was trading at $17.68 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $885.7M. The 52-week trading range was $10.96 to $25.95. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CDNA - Latest Insights

CDNA
Sep 16, 2026, 4:06 PM EDT
Filing Type: 8-K/A
Importance Score:
8
Price at Filing: $53.55
Real-time Price: $54.15 info
Change: +$0.600 (+1%) info
Market Cap: $2.801B info
CDNA
Aug 03, 2026, 7:33 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $44.99
Real-time Price: $54.15 info
Change: +$9.16 (+20%) info
Market Cap: $2.801B info
CDNA
Aug 01, 2026, 3:14 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $42.99
Real-time Price: $54.15 info
Change: +$11.16 (+26%) info
Market Cap: $2.801B info
CDNA
Jul 30, 2026, 4:04 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $41.00
Real-time Price: $54.15 info
Change: +$13.15 (+32%) info
Market Cap: $2.801B info
CDNA
Jul 30, 2026, 4:03 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $41.00
Real-time Price: $54.15 info
Change: +$13.15 (+32%) info
Market Cap: $2.801B info